Welcome to MorphoSys

Founded some 20 years ago, MorphoSys is today one of the world's leading biotechnology companies. From a pure antibody platform enterprise, MorphoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model. The Company’s aim is to continue pushing the boundaries of antibody generation in the industry – to engineer the medicines of tomorrow.


Innovation Capital

A new initiative through which MorphoSys provides innovation capital to promising start-ups.


Annual Report 2013

Have a look at MorphoSys's Annual Report 2013



  • 23/07/2014 // MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

    more …

  • 18/07/2014 // MorphoSys Receives Additional Patents on Novel Antibody Platform Ylanthia in the US and First Patent in China

    more …

Find more releases in the news overview


MorphoSys is interested in antibodies and biologics at late preclinical or early clinical stages.


Q2 2014 Results

MorphoSys will publish its first six months' 2014 results on July 28, 2014.